Earnshaw SR, Brogan A, Brodtkorb TH. Budget impact analysis II - applications & design issues. Presented at the ISPOR 2019 European Conference; November 3, 2019. Copenhagen, Denmark. Previously presented at the ISPOR 20th Annual International Meeting.
Brogan AJ, Talbird SE, Davis AE, Wild L, Flanagan D. Is increased screening and early antiretroviral treatment for HIV-1 worth the investment? An analysis of the public health and economic impact of improvement in the UK. HIV Med. 2019 Nov;20(10):668-80. doi: 10.1111/hiv.12788
Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2019 ISPOR 24th Annual International Meeting; May 19, 2019. New Orleans, LA. Previously presented at the ISPOR 20th Annual International Meeting.
Earnshaw SR, Javitt JC, Zlateva GP, Pleil AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing Macugen® to Visudyne®. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy.
Earnshaw SR, Javitt JC, Graham CN, Brogan AJ, Zlateva GP, Shah S, Adamis AP. Modeling treatments for subfoveal choroidal neovascularization secondary to age-related macular degeneration: cost-effectiveness methods. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy. [abstract] Value Health. 2005 Nov; 8(6):A179.
Earnshaw SR, Javitt JC, Zlateva GP, Pleil AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing early and late Macugen® treatment. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy. [abstract] Value Health. 2005 Nov; 8(6).
Ettinger B, Earnshaw SR, Brogan AJ, Graham CN, Amonkar MM, Baran R. Modeled cost impact of persistence with bisphosphonate therapy for women with postmenopausal osteoporosis. Poster presented at the Academy of Managed Care Pharmacy 17th Annual Meeting & Showcase; April 23, 2005.
Earnshaw SR, Brogan AJ, Graham CN, Amonkar MM, Baran R, Hebborn A. The impact of persistency on economic models for bisphosphonate therapy in osteoporosis. Poster presented at the 5th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; March 26, 2005. Rome, Italy.
Strickland A, Brogan AJ, Krauss J, Martindale R, Cresci G. Is the use of specialized nutritional formulations a cost-effective strategy? A national database evaluation. J Parenter Enter Nutr. 2005 Jan 1;29(1 Suppl):S81-91.
Brogan AJ, Stidham S. A note on separation in mean-lower-partial-moment portfolio optimization with fixed and moving targets. IIE Trans. 2005 Jan 1;37(10):901-6.